Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.

         Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.

Expands Multi-Modality Platform Capability

PR Newswire

SAN DIEGO, Nov. 23, 2012

SAN DIEGO, Nov. 23, 2012 /PRNewswire/ --Volcano Corporation (Nasdaq: VOLC), a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announced that it has entered into a definitive agreement to
acquire Sync-Rx Ltd., a privately-held company based in Israel that develops
advanced software applications that optimize and facilitate transcatheter
cardiovascular interventions using automated online image processing. It is
anticipated the transaction will close within the next 30 days.

"This transaction represents a strategic step in the advancement of our
multi-modality platform," said Scott Huennekens, President and Chief Executive
Officer of Volcano Corporation. "Sync-Rx's technology provides Volcano with a
platform on which to build a range of advanced software features that will aid
clinical decision-making by providing angiography and intra-body image
enhancement, measurements and non-invasive imaging and intravascular
co-registration capabilities, and future opportunities in physiology and
peripheral and minimally invasive structural heart therapy guidance. We are
excited about the Sync-Rx team joining Volcano and establishing a footprint in
Israel, given the breadth and depth of medical imaging and software talent
there."

Recent trends impacting Percutaneous Coronary Interventions (PCI) include the
heightened scrutiny of health care costs, resulting in the need to validate
treatment and outcomes with evidence as well as documentation of results for
quality metrics and reimbursement support, specifically regarding
appropriateness to stent and the results of the stenting. Volcano is focused
on guiding and optimizing  the delivery of minimally invasive therapies
utilizing visualization, physiology, and other technologies to help clinicians
achieve a more personalized treatment path for their patients as well as
documenting outcomes.

"Sync-Rx's technology will allow Volcano to better integrate and present a
wide variety of data in an intuitive manner that creates more meaningful
information for the physician and documentation for the hospital," added Mr.
Huennekens. "We see the technology being incorporated seamlessly into our
existing multi-modality system with the ability in the future to co-register
IVUS images directly on to the angiogram. Future applications for the Sync-Rx
technology in other areas include co-registration of non-invasive imaging with
real time intra-body physiology measurements and IVUS peripheral, forward
looking IVUS, forward looking intra-cardiac (ICE), and OCT imaging."

About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a
broad suite of technologies that make imaging and therapy simpler, more
informative and less invasive. Our products empower physicians around the
world with a new generation of analytical tools that deliver more meaningful
information - using sound and light as the guiding elements. Founded in
cardiovascular care and expanding into other specialties, Volcano is changing
the assumption about what is possible in improving patient outcomes by
combining imaging and therapy together. For more information, visit the
company's website at www.volcanocorp.com.

About Sync-Rx
Sync-Rx, Ltd. develops software that optimizes and facilitates transcatheter
cardiovascular interventions using automated online image processing. The
company's current focus is on coronary catheterizations. Sync-Rx, Ltd. is
located in Netanya, Israel.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this press release that are not historical facts may be considered
"forward-looking statements," including: statements regarding the expected
closing of the transaction described above; the features and capabilities or
potential features and capabilities of the technologies of Sync-Rx; the
expected benefits to Volcano of the transaction; the complementary nature of
the Sync-Rx technologies to be acquired with Volcano's business, products and
technologies; the expected market, including its size, to be addressed by
Volcano's products and Sync Rx's products; future operations of the Sync-Rx
business; and the benefits or potential benefits of Volcano's products and
procedures. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that may cause
Volcano's actual results to differ materially and adversely from the
statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ include the risk that the
transaction described above is not completed; the risk that benefits of the
transaction described above are not realized; the effect of competitive
factors and Volcano's reactions to those factors; purchasing decisions with
respect to Volcano's products; the pace and extent of market adoption of
Volcano's products and technologies; uncertainty in the process of obtaining
regulatory approval or clearance for Volcano's products or devices; the
success of Volcano's growth strategies; risks associated with Volcano's
international operations; timing and achievement of product development
milestones; outcome of ongoing or future litigation; the impact and benefits
of market development; our ability to protect our intellectual property;
dependence upon third parties; unexpected new data, safety and technical
issues; market conditions and other risks inherent to medical device
development and commercialization. These and additional risks and
uncertainties are more fully described in Volcano's filings made with the
Securities and Exchange Commission, including our most recent quarterly report
on Form 10-Q, and other filings made with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking statements,
which speak only as of the date they are made. Volcano disclaims any
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to
reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation

Website: http://www.volcanocorp.com
Contact: Media contact: Edrienne Brandon, ebrandon@volcanocorp.com,
+1-858-720-4136; Investor contact: Neal Rosen, nrosen@volcanocorp.com,
+1-650-458-3014